Aya Haggiagi, MD
- Assistant Professor of Neurology at CUMC
Aya Haggiagi, MD is an assistant professor of neurology at CUIMC, in the Division of Neuro-Oncology. Dr. Haggiagi is board certified in Neurology and Neuro-Oncology. She graduated with highest honors from the University of Al-Fateh School of Medicine in Tripoli, Libya. She subsequently completed a postdoctoral research fellowship in the Department of Pathology and Cell Biology at Columbia, under the mentorship of Dr. Michael Shelanski, where her research focused on biochemical and genetic changes in neurofibrillary tangle predominant dementia. Dr. Haggiagi then pursued her medicine internship training at Westchester Medical Center, followed by neurology residency at NewYork-Presbyterian/Columbia University Irving Medical Center. After residency, she completed a two-year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Haggiagi was an attending physician and an investigator at Memorial Sloan Kettering Cancer Center prior to returning to NYP/CUIMC. She is the recipient of the Society for Neuro-Oncology 2017 Best Poster Award. Her research interests include the development of clinical trials, precision medicine, and neurologic complications of immunotherapy.
Dr. Aya Haggiagi research interest is in the development of and participation in clinical trials using investigational treatments for newly diagnosed and recurrent brain tumors. She is particularly interested in clinical trials targeting specific genetic alterations identified with molecular profiling of the tumors.
Precision medicine using treatments targeting specific genetic alterations identified with molecular profiling of the tumors is a major forward step in the field of Neuro-oncology. Dr. Aya Haggiagi will be involved in several clinical trials using investigational treatments for newly diagnosed and recurrent brain tumors.
- Department of Neurology
Division of Neuro-oncology
Education & Training
- Al-Fateh University School of Medicine
- Internship: Westchester Medical Center
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
A RANDOMIZED OPEN-LABEL, MULTI-CENTER PIVOTAL STUDY OF ANG1005 COMPARED WITH PHYSICIAN?S BEST CHOICE IN HER2-NEGATIVE BREAST CANCER PATIENTS WITH NEWLY DIAGNOSED LEPTOMENINGEAL CARCINOMATOSIS AND PREVIOUSLY TREATED BRAIN METASTASES (ANGLED) (P&S Industry Clinical Trial)
Apr 4 2019 - Apr 4 2024